Envisia Therapeutics today announced that it has made two appointments to the company’s board of directors. Effective immediately, Adrienne Graves, Ph.D. and Gary Phillips, M.D. will join the board as non-executive members.
“We are extremely honored to have these two respected industry leaders join the Board of Directors of Envisia early in the lifecycle of our company, which we believe is paving the way for a potentially transformative line of innovative ocular therapeutics,” said Neal Fowler, Chief Executive Officer of Envisia Therapeutics. “Both appointments bring invaluable perspective and insights that are greatly complementary to that of our existing board, forming a team that will collectively help us position Envisia as a leader in developing cutting-edge solutions for the ophthalmology community.”
Help employers find you! Check out all the jobs and post your resume.
